Skip to Main Content

Advertisement

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 2, Issue 24
December 26 2018
Issue Cover

Table of Contents

POINT-COUNTERPOINT

Imatinib is still recommended for frontline therapy for CML
Clinical Trials & Observations
Andrew Hantel,Richard A. Larson

This article has a companion Counterpoint by Cortes.

View Articletitled, Imatinib is still recommended for frontline therapy for CML
A second-generation TKI should always be used as initial therapy for CML
Clinical Trials & Observations
Jorge E. Cortes

This article has a companion Point by Hantel and Larson.

View Articletitled, A second-generation TKI should always be used as initial therapy for CML

STIMULUS REPORT

Depletion of murine fetal hematopoietic stem cells with c-Kit receptor and CD47 blockade improves neonatal engraftment
Russell G. Witt,Bowen Wang,Quoc-Hung Nguyen,Carlo Eikani,Aras N. Mattis,Tippi C. MacKenzie
View Articletitled, Depletion of murine fetal hematopoietic stem cells with c-Kit receptor and CD47 blockade improves neonatal engraftment
Supplemental data

CLINICAL TRIALS AND OBSERVATIONS

Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Clinical Trials & Observations
Arnon P. Kater,Sabina Kersting,Yvette van Norden,Julie Dubois,Johan A. Dobber,Clemens H. Mellink,Ludo M. Evers,Fransien Croon-de Boer,John Schreurs,Ellen van der Spek,Hein Visser,Cecile Idink,Shulamiet Wittebol,Mels Hoogendoorn,Sanne H. Tonino,Mehrdad Mobasher,Mark-David Levin,on behalf of the HOVON CLL study group.
View Articletitled, Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL
Supplemental data
Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Clinical Trials & Observations
Gail J. Roboz,Sumithra J. Mandrekar,Pinkal Desai,Kristina Laumann,Alison R. Walker,Eunice S. Wang,Jonathan E. Kolitz,Bayard L. Powell,Eyal C. Attar,Wendy Stock,Clara D. Bloomfield,Jessica Kohlschmidt,Krzysztof Mrózek,Duane C. Hassane,Levi Garraway,Judit Jané-Valbuena,Michele Baltay,Adam Tracy,Guido Marcucci,Richard M. Stone,Richard A. Larson
View Articletitled, Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)
Supplemental data
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas
Clinical Trials & Observations
Erin G. Reid,David Looney,Frank Maldarelli,Ariela Noy,David Henry,David Aboulafia,Juan Carlos Ramos,Joseph Sparano,Richard F. Ambinder,Jeannette Lee,Ethel Cesarman,Sara Yahyaei,Ronald Mitsuyasu,William Wachsman,for the AIDS Malignancy Consortium
View Articletitled, Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas
Supplemental data

MYELOID NEOPLASIA

Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Clinical Trials & Observations
Raajit K. Rampal,John O. Mascarenhas,Heidi E. Kosiorek,Leah Price,Dmitriy Berenzon,Elizabeth Hexner,Camille N. Abboud,Marina Kremyanskaya,Rona Singer Weinberg,Mohamed E. Salama,Kamal Menghrajani,Vesna Najfeld,Lonette Sandy,Mark L. Heaney,Ross L. Levine,Ruben A. Mesa,Amylou C. Dueck,Judith D. Goldberg,Ronald Hoffman
View Articletitled, Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms
Supplemental data
Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53
Clinical Trials & Observations
Bridget K. Marcellino,Ronald Hoffman,Joseph Tripodi,Min Lu,Heidi Kosiorek,John Mascarenhas,Raajit K. Rampal,Amylou Dueck,Vesna Najfeld
View Articletitled, Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53

PLATELETS AND THROMBOPOIESIS

Platelet-specific deletion of SNAP23 ablates granule secretion, substantially inhibiting arterial and venous thrombosis in mice
Christopher M. Williams,Yong Li,Edward Brown,Alastair W. Poole
View Articletitled, Platelet-specific deletion of SNAP23 ablates granule secretion, substantially inhibiting arterial and venous thrombosis in mice

TRANSFUSION MEDICINE

A locus on chromosome 5 shows African ancestry–limited association with alloimmunization in sickle cell disease
Lesedi M. Williams,Zhihua Qi,Ken Batai,Stanley Hooker,Nancy J. Hall,Roberto F. Machado,Alice Chen,Sally Campbell-Lee,Yongtao Guan,Rick Kittles,Neil A. Hanchard
View Articletitled, A locus on chromosome 5 shows African ancestry–limited association with alloimmunization in sickle cell disease
Supplemental data

TRANSPLANTATION

HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment
Clinical Trials & Observations
Joseph Rimando,Michael Slade,John F. DiPersio,Peter Westervelt,Feng Gao,Chang Liu,Rizwan Romee
View Articletitled, HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment
Supplemental data
  • Cover Image

    Cover Image

    issue cover

    COVER FIGURE
    Cross section of a venous thrombus formed after ligation of the inferior vena cava in a mouse lacking the secretion regulator SNAP23 in its platelets. Thrombus size was markedly smaller than in control mice expressing SNAP23, but the remaining thrombus showed a platelet-containing, leukocyte-poor structure. The section was stained with CD41–fluorescein isothiocyanate (platelets, green), CD45-Alexa 568 (leukocytes, red), and DAPI (4′,6-diamidino-2-phenylindole, blue). See the article by Williams et al.

  • PDF Icon PDF LinkFront Matter
  • PDF Icon PDF LinkEditorial Board
All Issues

Advertisement

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy
Phillips NS, Mulrooney DA, Williams AM, et al. Neurocognitive impairment associated with chronic morbidity in long-term survivors of Hodgkin Lymphoma. Blood Adv. 2023;7(23):7270-7278.
Unleashed monocytic engagement in Sézary syndrome during the combination of anti-CCR4 antibody with type I interferon
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia
Race and ethnicity reporting and representation in hemophilia clinical trials

Advertisement

Advertisement

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement